Literature DB >> 2790792

Effect of duration of exposure to verapamil on vincristine activity against multidrug-resistant human leukemic cell lines.

C E Cass1, A Janowska-Wieczorek, M A Lynch, H Sheinin, A A Hindenburg, W T Beck.   

Abstract

Verapamil sensitizes multidrug-resistant cell lines to various heterocyclic anticancer drugs by inhibition of energy-dependent release of drug, presumably by interaction with membrane glycoproteins involved in drug efflux. This work assessed verapamil sensitization of human multidrug-resistant lymphocytic and myeloid leukemic cell lines (CEM/VLB100, HL-60/AR) to vincristine during exposures of short duration (4 h). When cells were transferred to drug-free medium immediately after simultaneous 4-h exposures to vincristine and verapamil, the antiproliferative activity of vincristine was not altered in CEM/VLB100 cells and was only moderately increased in HL-60/AR cells. In contrast, when cells were transferred to verapamil-containing medium, vincristine activity was greatly increased against both CEM/VLB100 and HL-60/AR cells. Verapamil enhanced accumulation and inhibited release of [3H]vincristine by CEM/VLB100 and HL-60/AR cells, indicating that the sensitization was due to an increase in cell-associated vincristine after transfer of cells to vincristine-free medium. Slot blot analysis of cellular RNA with the pMDR1 probe revealed high levels of expression of the mdr1 gene in CEM/VLB100 cells but no detectable expression in HL-60/AR cells. Consistent with this finding, polypeptides (Mr 170,000 to 180,000) that were recognized by a monoclonal antibody (C219) against P-glycoprotein were greatly overexpressed in CEM/VLB100 cells, but were expressed at low levels, if at all, in HL-60/AR cells. These results demonstrate the importance of duration of exposure to verapamil in reversing multidrug resistance, not only in cells that overexpress P-glycoprotein but also in cells, such as HL-60/AR, that express little, if any, P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790792

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Authors:  Thomas Clozel; ShaoNing Yang; Rebecca L Elstrom; Wayne Tam; Peter Martin; Matthias Kormaksson; Samprit Banerjee; Aparna Vasanthakumar; Biljana Culjkovic; David W Scott; Sarah Wyman; Micheal Leser; Rita Shaknovich; Amy Chadburn; Fabrizio Tabbo; Lucy A Godley; Randy D Gascoyne; Katherine L Borden; Giorgio Inghirami; John P Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2013-08-16       Impact factor: 39.397

Review 2.  Cellular drug efflux and reversal therapy of cancer.

Authors:  P W Wigler
Journal:  J Bioenerg Biomembr       Date:  1996-06       Impact factor: 2.945

3.  Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines.

Authors:  E Roller; B Klumpp; J Krause; M Eichelbaum; K Schumacher
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells.

Authors:  J E Gervasoni; R N Taub; M Rosado; S Krishna; V J Stewart; D M Knowles; K Bhalla; D D Ross; M A Baker; J Lutzky
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Reversal of multidrug resistance by phenothiazines and structurally related compounds.

Authors:  A Ramu; N Ramu
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B.

Authors:  T C Chou; X G Zhang; A Balog; D S Su; D Meng; K Savin; J R Bertino; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

Review 7.  Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drug.

Authors:  M S Center
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 8.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

9.  In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.

Authors:  J Soudon; M Berlion; C Lucas; P Haddad; J P Bizzari; F Calvo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata.

Authors:  T Parkinson; D J Falconer; C A Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.